Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANI PHARMACEUTICALS INCANIP · Entity 4638 | Director | March 15, 2018 | March 19, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANI PHARMACEUTICALS INC
Report date March 15, 2018 · Filed March 19, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 289,003 |
Last balance in matching sequence
After 2018-03-19 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-03-15 · Sale · Disposed 1,902 · Balance 294,316 F1: This transaction was executed in multiple trades at prices ranging from $61.00 to $62.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Held by Argentum Capital Partners II. L.P., which the Reporting Person may be deemed to be a beneficial owner pursuant to rule 16a-1(a)(1). Row 2 · 2018-03-19 · Sale · Disposed 5,313 · Balance 289,003 F3: This transaction was executed in multiple trades at prices ranging from $60.50 to $60.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Held by Argentum Capital Partners II. L.P., which the Reporting Person may be deemed to be a beneficial owner pursuant to rule 16a-1(a)(1). |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $61.00 to $62.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: Held by Argentum Capital Partners II. L.P., which the Reporting Person may be deemed to be a beneficial owner pursuant to rule 16a-1(a)(1).
F3: This transaction was executed in multiple trades at prices ranging from $60.50 to $60.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 19, 2018 Filed Mar 19, 2018 20:54 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 5,313 | $60.62 | $322,074.06 |
DisclosureSEC source: 0001144204-18-015633 · tv488937_form4.xml · nonDerivative · entry 2 RAYNOR DANIEL · CIK 0001068854 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 289,003 F3 · price: This transaction was executed in multiple trades at prices ranging from $60.50 to $60.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Held by Argentum Capital Partners II. L.P., which the Reporting Person may be deemed to be a beneficial owner pursuant to rule 16a-1(a)(1). Read SEC document |
| March 15, 2018 Filed Mar 19, 2018 20:54 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 1,902 | $61.50 | $116,973.00 |
DisclosureSEC source: 0001144204-18-015633 · tv488937_form4.xml · nonDerivative · entry 1 RAYNOR DANIEL · CIK 0001068854 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 294,316 F1 · price: This transaction was executed in multiple trades at prices ranging from $61.00 to $62.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Held by Argentum Capital Partners II. L.P., which the Reporting Person may be deemed to be a beneficial owner pursuant to rule 16a-1(a)(1). Read SEC document |
| March 14, 2018 Filed Mar 14, 2018 21:33 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 1,919 | $62.02 | $119,016.38 |
DisclosureSEC source: 0001144204-18-014708 · tv488553_form4.xml · nonDerivative · entry 4 RAYNOR DANIEL · CIK 0001068854 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 296,218 F5 · price: This transaction was executed in multiple trades at prices ranging from $62.00 to $62.09. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Held by Argentum Capital Partners II. L.P., which the Reporting Person may be deemed to be a beneficial owner pursuant to rule 16a-1(a)(1) Read SEC document |
| March 13, 2018 Filed Mar 14, 2018 21:33 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 4,117 | $62.59 | $257,683.03 |
DisclosureSEC source: 0001144204-18-014708 · tv488553_form4.xml · nonDerivative · entry 3 RAYNOR DANIEL · CIK 0001068854 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 298,137 F4 · price: This transaction was executed in multiple trades at prices ranging from $62.50 to $63.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Held by Argentum Capital Partners II. L.P., which the Reporting Person may be deemed to be a beneficial owner pursuant to rule 16a-1(a)(1) Read SEC document |
| March 13, 2018 Filed Mar 14, 2018 21:33 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 14,000 | $61.81 | $865,340.00 |
DisclosureSEC source: 0001144204-18-014708 · tv488553_form4.xml · nonDerivative · entry 2 RAYNOR DANIEL · CIK 0001068854 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 302,254 F3 · price: This transaction was executed in multiple trades at prices ranging from $61.51 to $62.17. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Held by Argentum Capital Partners II. L.P., which the Reporting Person may be deemed to be a beneficial owner pursuant to rule 16a-1(a)(1) Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 21:33 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 7,928 | $62.88 | $498,512.64 |
DisclosureSEC source: 0001144204-18-014708 · tv488553_form4.xml · nonDerivative · entry 1 RAYNOR DANIEL · CIK 0001068854 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 316,254 F1 · price: This transaction was executed in multiple trades at prices ranging from $62.8223 to $63.037. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Held by Argentum Capital Partners II. L.P., which the Reporting Person may be deemed to be a beneficial owner pursuant to rule 16a-1(a)(1) Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 22:11 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantStock Options · Derivative | 2,000 | $0.00 Strike: $49.51 | $0.00 |
DisclosureSEC source: 0001144204-17-018967 · v463554_form4.xml · derivative · entry 2 RAYNOR DANIEL · CIK 0001068854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2027-03-30 F1 · security: The restricted stock and stock options vest on the first anniversary of the grant date. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 22:11 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-018967 · v463554_form4.xml · nonDerivative · entry 1 RAYNOR DANIEL · CIK 0001068854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,110 F1 · security: The restricted stock and stock options vest on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.